Traduction de «international non-proprietary name » (Anglais → Français) :

The Council adopted a regulation concerning the provision of duty-free treatment for specified pharmaceutical active ingredients bearing an "international non-proprietary name" (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals (59/10).

Qualitative and quantitative particulars of all the constituents of the medicinal product, and the international non-proprietary name recommended by the World Health Organisation, where such a name for the medicinal product exists, or the internationally approved chemical name ;

name of the veterinary medicinal product and its active substances, expressed qualitatively and quantitatively, using, wherever they exist, the international non-proprietary names recommended by the World Health Organisation, and stating the name authorised in each of the Member States whenever the medicinal product has been authorised, under the procedure set out in Articles 31 to 43, under different names in the various Member States concerned.

The plan involves a large reduction in overheads, a cut in staff numbers to 7 800 by the end of 2003 and a refocusing on the company's strengths, namely GCOS proprietary servers, IT services linked to Bull products and the development of a new range of open servers.

Further to the conclusions of the Uruguay Round on duty-free treatment for pharmaceutical products and an initial review of the list of products concerned by the WTO Council for Trade in Goods, the Council decided, as from 1 April 1997, to extend duty-free treatment to certain active ingredients bearing an "international non-proprietary name" (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals.

COUNCIL RESOLUTION DESIGNED TO IMPLEMENT THE OUTLINES OF AN INDUSTRIAL POLICY IN THE PHARMACEUTICAL SECTOR IN THE EUROPEAN UNION THE COUNCIL Having regard to the Commission communication of 14 September 1994 entitled "An industrial competitiveness policy for the European Union"; Recalling its Resolution of 21 November 1994 on strengthening the competitiveness of Community industry [10] , and its conclusions of 7 April 1995 on an industrial competitiveness policy; Having regard to the communication of 2 March 1994 from the Commission to the Council and the European Parliament on the outlines of an industrial policy for the pharmaceutical sector in the European Union; Whereas the European Union has an important role to play in creating a f ...[+++]avourable environment for the expansion of activities relating to research, development, production and distribution of medicinal products and in encouraging the development of an innovative and effective European pharmaceutical industry in terms of competitiveness on the world market; Whereas European industrial policy must necessarily take account of the special nature of this sector, which relates both to public health and to social policy; whereas social security systems bear a considerable proportion of pharmaceutical expenditure; whereas this is a matter which falls within the competence of the Member States; Whereas the European Union has the responsibility of sketching out guidelines for the promotion of Community activities in this sector, HAS ADOPTED THIS RESOLUTION: I. WITH RESPECT TO THE SITUATION IN THE PHARMACEUTICAL INDUSTRY 1. recalls that the European pharmaceutical industry plays an essential role in public health, remains a high-technology industry with considerable added value, which is particularly successful, generates highly skilled jobs and makes a significant contribution to the Union's balance of trade; 2. considers that, now that it is facing increasingly intense international competition, the Euro ...